Basic Information

Professional Memberships

• From 2007, To Present

  日本肺癌学会
• 日本臨床腫瘍学会
• 日本呼吸器学会
• 日本内科学会

Academic Degree

• 博士（医学）(京都大学)

Research History

• From Apr. 2018, To Present

  Kyoto University, 腫瘍薬物治療学講座, 特定病院助教
• From Apr. 2013, To Mar. 2018

  京都大学医学部附属病院, 呼吸器内科
• From Apr. 2009, To Mar. 2013

  京都大学大学院医学研究科, 呼吸器内科学
• From Apr. 2004, To Mar. 2009

  済生会中津病院, 呼吸器内科
• From May 2003, To Mar. 2004

  京都大学医学部附属病院, 研修医

Language of Instruction

• Japanese

ID,URL

• ORCID ID

  0000-0001-6421-7266

• J-Global ID

  201401030358006471

• Researcher number

  10725930

researchmap URL

• https://researchmap.jp/7000010610

Research

Research Topics, Overview of the research

• Research Topics

  Association of ALDH7A1 overexpression with chemotherapy resistance and cancer stem cell in lung cancer

• Overview of the research

  Aldehyde dehydrogenases (ALDHs) play a major role in the oxidation of aldehydes. Certain isoforms of ALDH is related to cancer stem cells (CSCs) responsible for tumor initiating, drug resistance and metastasis. ALDH1A1 and ALDH3A1 has been known for CSC marker of lung cancer. Since these two isoforms and ALDH7A1 are involved in cellular structural and osmoregulatory function, we focused on function of ALDH7A1 in lung cancer.

Research Areas

• Life sciences, Tumor diagnostics and therapeutics
• Life sciences, Respiratory medicine

Papers

• Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer

  Kentaro Tanaka; Kenji Chamoto; Sho Saeki; Ryusuke Hatae; Yuki Ikematsu; Kazuko Sakai; Nobuhisa Ando; Kazuhiro Sonomura; Shinsuke Kojima; Masanori Taketsuna; Young Hak Kim; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Tomoko Hirano; Fumihiko Matsuda; Toyohiro Hirai; Kazuto Nishio; Takuro Sakagami; Masanori Fukushima; Yoichi Nakanishi; Tasuku Honjo; Isamu Okamoto

  Science Translational Medicine, 14 Dec. 2022

  
• Abstract 1830: A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer

  Takahiro Tsuji; Hiroaki Ozasa; Takashi Nomizo; Tomoko Funazo; Yuto Yasuda; Yuichi Sakamori; Hironori Yoshida; Kiyoshi Uemasu; Hitomi Ajimizu; Ryoko Okutani; Shunsuke Aburaya; Wataru Aoki; Mitsuyoshi Ueda; Koh Furugaki; Yasushi Yoshimura; Toyohiro Hirai; Young Hak Kim

  Cancer Research, 01 Jul. 2018

  
• 両側肺門部リンパ節腫大が先行し、経過中に石灰化と肺多発結節影が出現した肺癌と悪性リンパ腫の合併症例

  曽根 尚之; 糸谷 涼; 池尾 聡; 嶋村 亜紀; 橋本 健太郎; 吉田 寛; 吉田 博徳; 阪森 優一; 平井 豊博

  気管支学, May 2022

  
• Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.

  Kentaro Hashimoto; Hiroaki Ozasa; Akihiko Yoshizawa; Hiroshi Yoshida; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Hitomi Ajimizu; Tomoko Funazo; Hironori Yoshida; Yuichi Sakamori; Toyohiro Hirai

  Oncology letters, Nov. 2022

  
• Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.

  Masatoshi Yamazoe; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Hiroshi Yoshida; Kentaro Hashimoto; Kazutaka Hosoya; Tatsuya Ogimoto; Hitomi Ajimizu; Hironori Yoshida; Ryo Itotani; Yuichi Sakamori; Kiyomitsu Kuninaga; Wataru Aoki; Toyohiro Hirai

  Cancer science, 26 Oct. 2022

  
• 腎生検が診断に有用であった抗PD-L1抗体による薬剤性間質性腎炎の一例

  大植 薫; 横井 秀基; 近藤 麻紀子; 阪森 優一; 南口 早智子; 松原 雄; 柳田 素子

  日本腎臓学会誌, Sep. 2021

  
• Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).

  Young Hak Kim; Hiroki Nagai; Hiroaki Ozasa; Yuichi Sakamori; Michiaki Mishima

  Biomedical reports, Sep. 2013, Peer-reviewed

  
• Phase II study of pemetrexed as first-line treatment in elderly (a parts per thousand yen75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901

  Young Hak Kim; Masataka Hirabayashi; Shinji Kosaka; Junichi Nikaidoh; Yasumichi Yamamoto; Masatoshi Shimada; Toshiya Toyazaki; Hiroki Nagai; Yuichi Sakamori; Michiaki Mishima

  CANCER CHEMOTHERAPY AND PHARMACOLOGY, Jun. 2013, Peer-reviewed

  
• Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer.

  Yuka Kuriyama; Young Hak Kim; Hiroki Nagai; Hiroaki Ozasa; Yuichi Sakamori; Michiaki Mishima

  Case reports in oncology, 2013, Peer-reviewed

  
• Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer.

  Kazuihto Ueki; Yukinori Matsuo; Noriko Kishi; Masahiro Yoneyama; Hironori Yoshida; Yuichi Sakamori; Hiroaki Ozasa; Toyohiro Hirai; Takashi Mizowaki

  Journal of radiation research, 02 Jul. 2022

  
• Continuous morphine infusion for end-stage lung cancer patients

  Young Hak Kim; Chiyuki Okuda; Yuichi Sakamori; Katsuhiro Masago; Yosuke Togashi; Michiaki Mishima

  ONCOLOGY LETTERS, Mar. 2013, Peer-reviewed

  
• Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer.

  Yosuke Togashi; Katsuhiro Masago; Yutaka Ito; Yuichi Sakamori; Chiyuki Okuda; Akiko Fukuhara; Hiroki Nagai; Young Hak Kim; Michiaki Mishima

  Oncology letters, Feb. 2013, Peer-reviewed

  
• Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy.

  Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Hiroki Nagai; Yuichi Sakamori; Chiyuki Okuda; Young Hak Kim; Michiaki Mishima

  Oncology, 2013, Peer-reviewed

  
• Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma

  Yosuke Togashi; Katsuhiro Masago; Takeshi Kubo; Daichi Fujimoto; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Kaori Togashi; Michiaki Mishima

  MEDICAL ONCOLOGY, Dec. 2012, Peer-reviewed

  
• Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

  Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yuichi Sakamori; Chiyuki Okuda; Young Hak Kim; Tadashi Mio; Michiaki Mishima

  MEDICAL ONCOLOGY, Sep. 2012, Peer-reviewed

  
• Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non-Small-Cell Lung Cancer

  Young Hak Kim; Shinji Sumiyoshi; Seiji Hashimoto; Katsuhiro Masago; Yosuke Togashi; Yuichi Sakamori; Chiyuki Okuda; Tadashi Mio; Michiaki Mishima

  CLINICAL LUNG CANCER, Sep. 2012, Peer-reviewed

  
• Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO-cGMP signaling in lung adenocarcinoma cells in vitro and in vivo

  Hiroki Nagai; Hiroyasu Yasuda; Yukimasa Hatachi; Deng Xue; Takahiko Sasaki; Mutsuo Yamaya; Yuichi Sakamori; Yousuke Togashi; Katsuhiro Masago; Isao Ito; Young Hak Kim; Tadashi Mio; Michiaki Mishima

  INTERNATIONAL JOURNAL OF ONCOLOGY, Jul. 2012, Peer-reviewed

  
• Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor

  Kaoru Irisa; Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yukimasa Hatachi; Akiko Fukuhara; Yuichi Sakamori; Yung Hak Kim; Tadashi Mio; Michiaki Mishima

  MEDICAL ONCOLOGY, Mar. 2012, Peer-reviewed

  
• Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer

  Katsuhiro Masago; Shiro Fujita; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Kaoru Irisa; Yuichi Sakamori; Tadashi Mio; Michiaki Mishima

  ONCOLOGY REPORTS, Oct. 2011, Peer-reviewed

  
• Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

  Yosuke Togashi; Katsuhiro Masago; Shiro Fujita; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Yuichi Sakamori; Young Hak Kim; Tadashi Mio; Michiaki Mishima

  LUNG CANCER, Oct. 2011, Peer-reviewed

  
• Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non-Small-Cell Lung Cancer With Pleural Effusion

  Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Young Hak Kim; Tadashi Mio; Ken-ichi Inui; Michiaki Mishima

  CLINICAL LUNG CANCER, Sep. 2011, Peer-reviewed

  
• Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer

  Katsuhiro Masago; Shiro Fujita; Tadashi Mio; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Kaoru Irisa; Yuichi Sakamori; Michiaki Mishima

  MEDICAL ONCOLOGY, Mar. 2011, Peer-reviewed

  
• EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy

  Young Hak Kim; Katsuhiro Masago; Yosuke Togashi; Yuichi Sakamori; Chiyuki Okuda; Tadashi Mio; Michiaki Mishima

  ONCOLOGY LETTERS, Mar. 2011, Peer-reviewed

  
• Association of the transforming growth factor beta 1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer

  Yosuke Togashi; Katsuhiro Masago; Shiro Fujita; Young Hak Kim; Yuichi Sakamori; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Tadashi Mio; Michiaki Mishima

  ONCOLOGY REPORTS, Feb. 2011, Peer-reviewed

  
• Association of Diffuse, Random Pulmonary Metastases, Including Miliary Metastases, With Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma

  Yosuke Togashi; Katsuhiro Masago; Takeshi Kubo; Yuichi Sakamori; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Tadashi Mio; Kaori Togashi; Michiaki Mishima

  CANCER, Feb. 2011, Peer-reviewed

  
• Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer

  Katsuhiro Masago; Shiro Fujita; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Kaoru Irisa; Hiroki Nagai; Yuichi Sakamori; Yosuke Togashi; Tadashi Mio; Michiaki Mishima

  CANCER CHEMOTHERAPY AND PHARMACOLOGY, Feb. 2011, Peer-reviewed

  
• Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

  Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Shiro Fujita; Young Hak Kim; Tadashi Mio; Ken-Ichi Inui; Michiaki Mishima

  Case reports in oncology, 22 Apr. 2010, Peer-reviewed

  
• COPD合併進行非小細胞肺癌患者へのCOPD薬物治療の意義(2nd Report)

  國永 清光; 小笹 裕晃; 味水 瞳; 阪森 優一; 吉田 博徳; 糸谷 涼; 野溝 岳; 金 永学; 佐藤 晋; 平井 豊博

  日本呼吸器学会誌, Apr. 2021

  
• Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindlecellcarcinoma

  Tsuji Takahiro; Kim Young Hak; Ozasa Hiroaki; Sakamori Yuichi; Nagai Hiroki; Ajimizu Hitomi; Yagi Yoshitaka; Furukawa Atsuyuki; Haga Hironori; Mishima Michiaki

  Respiratory Medicine Case Reports, 01 May 2015

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

  Hitomi Ajimizu; Hiroaki Ozasa; Susumu Sato; Tomoko Funazo; Yuichi Sakamori; Takashi Nomizo; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Kentaro Ueno; Young Hak Kim; Shigeo Muro; Toyohiro Hirai

  Scientific reports, 08 Dec. 2021

  
• PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.

  Hironori Yoshida; Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Yuto Yasuda; Hitomi Ajimizu; Masatoshi Yamazoe; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Ryo Itotani; Yuichi Sakamori; Young Hak Kim; Toyohiro Hirai

  European journal of cancer (Oxford, England : 1990), Feb. 2021, Peer-reviewed

  
• Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.

  Tomohiro Kondo; Junichi Matsubara; Pham Nguyen Quy; Keita Fukuyama; Motoo Nomura; Taro Funakoshi; Keitaro Doi; Yuichi Sakamori; Masahiro Yoshioka; Akira Yokoyama; Masashi Tamaoki; Tadayuki Kou; Kenshiro Hirohashi; Atsushi Yamada; Yoshihiro Yamamoto; Sachiko Minamiguchi; Masakazu Nishigaki; Takahiro Yamada; Masashi Kanai; Shigemi Matsumoto; Manabu Muto

  Cancer science, Jan. 2021

  
• 進行非小細胞肺癌におけるCBDCA+PEM+BEV療法後のBEV、PEM、PEM+BEV維持療法を比較したランダム化第II相試験

  金田 俊彦; 吉田 博徳; 金 永学; 阪森 優一; 永井 宏樹; 小笹 裕晃; 吉岡 弘鎮; 仲川 宏昭; 富井 啓介; 岡田 あすか; 吉村 健一; 平林 正孝; 平井 豊博

  肺癌, Oct. 2020

  
• Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.

  Tomoko Funazo; Takahiro Tsuji; Hiroaki Ozasa; Koh Furugaki; Yasushi Yoshimura; Tetsuya Oguri; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Yuichi Sakamori; Hironori Yoshida; Young Hak Kim; Toyohiro Hirai

  Molecular cancer therapeutics, Jun. 2020, Peer-reviewed

  
• A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.

  Hironori Yoshida; Young Hak Kim; Yuichi Sakamori; Hiroki Nagai; Hiroaki Ozasa; Toshihiko Kaneda; Hiroshige Yoshioka; Hiroaki Nakagawa; Keisuke Tomii; Asuka Okada; Kenichi Yoshimura; Masataka Hirabayashi; Toyohiro Hirai

  Anticancer research, May 2020

  
• MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.

  Yuto Yasuda; Hiroaki Ozasa; Young Hak Kim; Masatoshi Yamazoe; Hitomi Ajimizu; Tomoko Yamamoto Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Naoki Nakajima; Toshi Menju; Akihiko Yoshizawa; Hiroshi Date; Toyohiro Hirai

  Cell death & disease, 09 Mar. 2020, Peer-reviewed

  
• Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.

  Ryusuke Hatae; Kenji Chamoto; Young Hak Kim; Kazuhiro Sonomura; Kei Taneishi; Shuji Kawaguchi; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Maryam Akrami; Sidonia Fagarasan; Izuru Masuda; Yasushi Okuno; Fumihiko Matsuda; Toyohiro Hirai; Tasuku Honjo

  JCI insight, 30 Jan. 2020, Peer-reviewed

  
• YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Yamamoto Funazo; Koh Furugaki; Yasushi Yoshimura; Masatoshi Yamazoe; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Hironori Yoshida; Yuichi Sakamori; Hiroaki Wake; Mitsuyoshi Ueda; Young Hak Kim; Toyohiro Hirai

  Nature communications, 03 Jan. 2020, Peer-reviewed

  
• Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.

  Hironori Yoshida; Young Hak Kim; Shigeaki Iwatsubo; Chikara Sakaguchi; Yuichi Sakamori; Hiroki Nagai; Hiroaki Ozasa; Tadashi Mio; Toyohiro Hirai

  Oncology, 2020, Peer-reviewed

  
• Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer

  HIRONORI YOSHIDA; HIROKI NAGAI; YUICHI SAKAMORI; HIROAKI OZASA; TAKASHI NISHIMURA; KEISUKE TOMII; TOYOHIRO HIRAI; YUKINORI MATSUO; YUSUKE IIZUKA; TAKASHI MIZOWAKI; KENICHI YOSHIMURA; YOUNG HAK KIM

  In Vivo, 2020, Peer-reviewed

  
• Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.

  Tomoko Yamamoto Funazo; Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Yuto Yasuda; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim

  Scientific reports, 19 Nov. 2019, Peer-reviewed

  
• 当院における非小細胞肺癌脳転移に対する放射線治療成績

  花澤 豪樹; 松尾 幸憲; 宇藤 恵; 竹花 恵一; 岸 徳子; 溝脇 尚志; 金 永学; 阪森 優一

  肺癌, Aug. 2019

  
• Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.

  Ichiro Yamauchi; Akihiro Yasoda; Shigemi Matsumoto; Yuichi Sakamori; Young Hak Kim; Motoo Nomura; Atsushi Otsuka; Toshinari Yamasaki; Ryoichi Saito; Morimasa Kitamura; Toshio Kitawaki; Masakatsu Hishizawa; Nobuko Kawaguchi-Sakita; Toshihito Fujii; Daisuke Taura; Masakatsu Sone; Nobuya Inagaki

  PloS one, 2019

  
• Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Funazo; Koh Furugaki; Yasushi Yoshimura; Hitomi Ajimizu; Ryoko Okutani; Yuto Yasuda; Takashi Nomizo; Kiyoshi Uemasu; Koichi Hasegawa; Hironori Yoshida; Yoshitaka Yagi; Hiroki Nagai; Yuichi Sakamori; Mitsuyoshi Ueda; Toyohiro Hirai; Young Hak Kim

  Molecular cancer research : MCR, Jan. 2019, Peer-reviewed

  
• Nivolumab in non-small-cell lung cancer with EGFR mutation

  H. Yoshida; Y.H. Kim; H. Ozasa; H. Nagai; Y. Sakamori; T. Tsuji; T. Nomizo; Y. Yasuda; T. Funazo; T. Hirai

  Annals of Oncology, Mar. 2018, Peer-reviewed

  
• Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer

  HIRONORI YOSHIDA; YOUNG HAK KIM; HIROAKI OZASA; YUICHI SAKAMORI; TAKAHIRO TSUJI; TAKASHI NOMIZO; YUTO YASUDA; TOMOKO YAMAMOTO; HITOMI AJIMIZU; TOYOHIRO HIRAI

  In Vivo, 2018, Peer-reviewed

  
• Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim

  Molecular and clinical oncology, Oct. 2017, Peer-reviewed

  
• Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

  Takahiro Tsuji; Yuichi Sakamori; Hiroaki Ozasa; Yoshitaka Yagi; Hitomi Ajimizu; Yuto Yasuda; Tomoko Funazo; Takashi Nomizo; Hironori Yoshida; Hiroki Nagai; Ken Maeno; Tetsuya Oguri; Toyohiro Hirai; Young Hak Kim

  Oncotarget, 22 Sep. 2017, Peer-reviewed

  
• Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

  Yuto Yasuda; Yasuyo Nishikawa; Yuichi Sakamori; Makoto Terao; Kentaro Hashimoto; Tomoko Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Hiroki Nagai; Hiroaki Ozasa; Toyohiro Hirai; Young Hak Kim

  Molecular and clinical oncology, Aug. 2017, Peer-reviewed

  
• EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

  Hironori Yoshida; Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Takahiro Tsuji; Takashi Nomizo; Tomoko Funazo; Yuto Yasuda; Toyohiro Hirai

  Anticancer research, May 2017

  
• Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

  Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Yuto Yasuda; Hironori Yoshida; Yoshitaka Yagi; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim

  Scientific reports, 23 Mar. 2017, Peer-reviewed

  
• Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.

  Hironori Yoshida; Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Takashi Nakaoku; Yoshitaka Yagi; Takahiro Tsuji; Takashi Nomizo; Michiaki Mishima

  Molecular and clinical oncology, Jul. 2016, Peer-reviewed

  
• Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

  Hiroshi Shima; Hiroaki Ozasa; Takahiro Tsuji; Hitomi Ajimizu; Takashi Nomizo; Yoshitaka Yagi; Yuichi Sakamori; Hiroki Nagai; Sachiko Minamiguchi; Young Hak Kim; Michiaki Mishima

  Molecular and clinical oncology, May 2016

  
• EGFR遺伝子変異陽性肺癌症例におけるerlotinib/bevacizumab併用療法の後方視的検討

  永井 宏樹; 金 永学; 味水 瞳; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 中奥 敬史; 阪森 優一; 小笹 裕晃; 三嶋 理晃

  肺癌, Oct. 2015

  
• 再発小細胞肺癌に対するnab-paclitaxelの有用性の検討

  吉田 博徳; 金 永学; 野溝 岳; 辻 貴宏; 中奥 敬史; 八木 由生; 阪森 優一; 永井 宏樹; 小笹 裕晃; 三嶋 理晃

  肺癌, Oct. 2015

  
• Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed

  YUICHI SAKAMORI; YOUNG HAK KIM; HIRONORI YOSHIDA; TAKASHI NAKAOKU; HIROKI NAGAI; YOSHITAKA YAGI; HIROAKI OZASA; MICHIAKI MISHIMA

  Molecular and Clinical Oncology, Mar. 2015, Peer-reviewed, Lead author

  
• Crizotinib耐性ALK陽性肺癌の脳転移に対し、Alectinibが著効した1例

  味水 瞳; 金 永学; 小笹 裕晃; 永井 宏樹; 阪森 優一; 八木 由生; 吉田 博徳; 中奥 敬史; 三嶋 理晃

  肺癌, Feb. 2015

  
• 当院でのCrizotinib投与症例9例の検討

  小笹 裕晃; 八木 由生; 中奥 敬史; 吉田 博徳; 阪森 優一; 永井 宏樹; 金 永学; 三嶋 理晃; 伊達 洋至

  肺癌, Apr. 2014

  
• 当院におけるEGFR遺伝子変異陽性肺癌に対するerlotinib使用症例の臨床的検討

  島 寛; 金 永学; 阪森 優一; 中奥 敬史; 八木 由生; 吉田 博徳; 永井 宏樹; 小笹 裕晃; 三嶋 理晃

  肺癌, Apr. 2014

  
• 非小細胞肺癌(非扁平上皮癌)に対する2次・3次治療としてのエルロチニブ/ベバシズマブ併用療法・第II相試験

  柳原 一広; 金 永学; 真砂 勝康; 冨樫 庸介; 阪森 優一; 平林 正孝; 二階堂 純一

  肺癌, Oct. 2013

  
• High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib

  Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Hironori Yoshida; Yoshitaka Yagi; Takashi Nakaoku; Michiaki Mishima

  Journal of Thoracic Oncology, Sep. 2013, Peer-reviewed

  
• Circulating tumor cells as a prognostic marker in metastatic non-small-cell lung cancer patients receiving chemotherapy.

  Yuichi Sakamori; Young Hak Kim; Hiroshige Yoshioka; Masataka Hirabayashi; Koichi Onaru; Motonari Fukui; Toshiki Hirata; Michiaki Mishima

  Journal of Clinical Oncology, 20 May 2013, Lead author

  
• Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.

  Young Hak Kim; Takashi Nishimura; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Toshiyuki Iwata; Hironobu Sunadome; Tomoko Nishimura; Michiaki Mishima

  Chemotherapy, 2013

  
• 進行期非小細胞癌による癌性胸水に対するベバシズマブ包含化学療法の有効性

  藤本 大智; 真砂 勝泰; 冨樫 庸介; 奥田 千幸; 阪森 優一; 金 永学; 三嶋 理晃

  肺癌, Oct. 2012

  
• Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.

  Togashi Yosuke; Masago Katsuhiro; Masuda Satohiro; Mizuno Tomoyuki; Fukudo Masahide; Ikemi Yasuaki; Sakamori Yuichi; Nagai Hiroki; Kim Young Hak; Katsura Toshiya; Mishima Michiaki

  Cancer chemotherapy and pharmacology, Sep. 2012

  
• Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.

  Togashi Yosuke; Masago Katsuhiro; Hamatani Yasuhiro; Sakamori Yuichi; Nagai Hiroki; Kim Young Hak; Mishima Michiaki

  Lung cancer (Amsterdam, Netherlands), Aug. 2012

  
• Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.

  Togashi Yosuke; Masago Katsuhiro; Handa Tomohiro; Tanizawa Kiminobu; Okuda Chiyuki; Sakamori Yuichi; Nagai Hiroki; Kim Young Hak; Mishima Michiaki

  Clinical lung cancer, Jul. 2012

  
• Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer

  Yuichi Sakamori; Katsuhiro Masago; Katsuyuki Ohmori; Yosuke Togashi; Hiroki Nagai; Chiyuki Okuda; Young Hak Kim; Satoshi Ichiyama; Michiaki Mishima

  Cancer Science, Jun. 2012, Peer-reviewed, Lead author

  
• Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

  Togashi Yosuke; Masago Katsuhiro; Fukudo Masahide; Tsuchido Yasuhiro; Okuda Chiyuki; Kim Young Hak; Ikemi Yasuaki; Sakamori Yuichi; Mio Tadashi; Katsura Toshiya; Mishima Michiaki

  Cancer chemotherapy and pharmacology, Oct. 2011

  
• 脳転移の治療 中枢神経転移を有する非小細胞肺癌患者におけるerlotinibの血清と髄液濃度の相関関係の検討

  冨樫 庸介; 真砂 勝泰; 福土 将秀; 奥田 千幸; 阪森 優一; 金 永学; 桂 敏也; 三嶋 理晃

  肺癌, Oct. 2011

  
• 間質性肺炎合併肺小細胞癌患者の予後の検討

  奥田 千幸; 冨樫 庸介; 真砂 勝泰; 半田 知宏; 谷澤 公伸; 阪森 優一; 金 永学; 三嶋 理晃

  肺癌, Oct. 2011

  
• 京大病院呼吸器内科病棟で塩酸モルヒネ持続注射が用いられた終末期肺癌患者のレトロスペクティブ解析

  金 永学; 冨樫 庸介; 奥田 千幸; 阪森 優一; 真砂 勝泰; 三嶋 理晃

  肺癌, Oct. 2011

  
• 進行非小細胞肺癌患者におけるEGFR遺伝子変異と全身性炎症反応との関係

  冨樫 庸介; 真砂 勝泰; 阪森 優一; 金 永学; 三嶋 理晃

  肺癌, Oct. 2011

  
• 2nd line以降の既治療非小細胞肺癌に対するベバシズマブ併用療法の臨床的検討

  阪森 優一; 金 永学; 奥田 千幸; 冨樫 庸介; 真砂 勝泰; 三尾 直士; 三嶋 理晃

  肺癌, Oct. 2011

  
• T790Mを有するgefitinib耐性非小細胞肺癌に対してerlotinibを使用しその濃度を測定した2症例

  藤本 大智; 冨樫 庸介; 真砂 勝泰; 阪森 優一; 金 永学; 三嶋 理晃; 福土 将秀; 桂 敏也

  肺癌, Oct. 2011

  
• Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).

  Tanaka Shiro; Sakamori Yuichi; Niimi Miyuki; Hazama Megumi; Kim Young H; Yanagihara Kazuhiro

  Trials, 12 May 2011

  
• Two Cases of Cancer-associated Retinopathy Combined with Small-cell Lung Cancer

  Yuichi Sakamori; Young Hak Kim; Chiyuki Okuda; Yosuke Togashi; Daisuke Kinose; Katsuhiro Masago; Tadashi Mio; Akihito Uji; Michiaki Mishima

  Japanese Journal of Clinical Oncology, May 2011, Peer-reviewed, Lead author

  
• Gefitinibとerlotinibの毒性の違い

  冨樫 庸介; 真砂 勝泰; 阪森 優一; 金 永学; 三尾 直士; 三嶋 理晃

  肺癌, Apr. 2011

  
• Pemetrexed投与による肝障害の検討

  阪森 優一; 金 永学; 奥田 千幸; 冨樫 庸介; 真砂 勝泰; 三尾 直士; 三嶋 理晃

  肺癌, Apr. 2011

  
• Pemetrexedが長期にわたり有効であった粘液産生型気管支肺胞上皮癌の1例

  奥田 千幸; 金 永学; 冨樫 庸介; 真砂 勝泰; 阪森 優一; 三尾 直士; 三嶋 理晃

  肺癌, Apr. 2011

  
• Long-term Survival in a Patient with Small-cell Lung Cancer Undergoing Hemodialysis Who Received Multiple Courses of Chemotherapy

  Y. Togashi; Y. H. Kim; K. Masago; Y. Sakamori; C. Okuda; T. Mio; M. Mishima

  Japanese Journal of Clinical Oncology, 01 Apr. 2011, Peer-reviewed

  
• Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients

  KATSUHIRO MASAGO; SHIRO FUJITA; YOSUKE TOGASHI; KAORU IRISA; YUICHI SAKAMORI; YUKIMASA HATACHI; AKIKO FUKUHARA; HIROKI NAGAI; YOUNG HAK KIM; TADASHI MIO; MICHIAKI MISHIMA

  Oncology Letters, Mar. 2011, Peer-reviewed

  
• Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity

  Chiyuki Okuda; Young Hak Kim; Kengo Takeuchi; Yosuke Togashi; Katsuhiro Masago; Yuichi Sakamori; Tadashi Mio; Michiaki Mishima

  Journal of Thoracic Oncology, Mar. 2011, Peer-reviewed

  
• Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy

  Katsuhiro Masago; Shiro Fujita; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Yuichi Sakamori; Tadashi Mio; Michiaki Mishima

  Clinical Lung Cancer, Jan. 2011, Peer-reviewed

  
• ランダムパターンを呈する彌漫性肺内転移とEGFR遺伝子変異との関連性についての検討

  冨樫 庸介; 真砂 勝泰; 久保 武; 金 永学; 阪森 優一; 三尾 直士; 富樫 かおり; 三嶋 理晃

  肺癌, Oct. 2010

  
• EGFR遺伝子変異陽性非小細胞肺癌の中枢神経系転移に対するEGFRチロシンキナーゼ阻害剤の有効性の検討

  冨樫 庸介; 真砂 勝泰; 金 永学; 阪森 優一; 三尾 直士; 三嶋 理晃

  肺癌, Oct. 2010

  
• 進行非小細胞肺癌悪性胸水貯留例におけるエルロチニブ及び代謝産物の薬物動態

  真砂 勝泰; 冨樫 庸介; 金 永学; 阪森 優一; 三尾 直士; 三嶋 理晃

  肺癌, Oct. 2010

  
• Infectious background of febrile advanced lung cancer patients who received chemotherapy

  KATSUHIRO MASAGO; AKIKO FUKUHARA; YUTAKA ITO; YUKIMASA HATACHI; KAORU IRISA; YUICHI SAKAMORI; YOSUKE TOGASHI; SHIRO FUJITA; YOUNG HAK KIM; TADASHI MIO; MICHIAKI MISHIMA

  Oncology Letters, Sep. 2010, Peer-reviewed

  
• Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

  Yosuke Togashi; Katsuhiro Masago; Masahide Fukudo; Tomohiro Terada; Shiro Fujita; Kaoru Irisa; Yuichi Sakamori; Young Hak Kim; Tadashi Mio; Ken-ichi Inui; Michiaki Mishima

  Journal of Thoracic Oncology, Jul. 2010, Peer-reviewed

  
• Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis

  Yosuke Togashi; Katsuhiro Masago; Masahide Fukudo; Tomohiro Terada; Yasuaki Ikemi; Young Hak Kim; Shiro Fujita; Kaoru Irisa; Yuichi Sakamori; Tadashi Mio; Ken-ichi Inui; Michiaki Mishima

  Journal of Thoracic Oncology, May 2010, Peer-reviewed

  
• Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride

  YOUNG HAK KIM; TADASHI MIO; KATSUHIRO MASAGO; KAORU IRISA; YUICHI SAKAMORI; MICHIAKI MISHIMA

  Oncology Letters, May 2010, Peer-reviewed

  
• 甲状腺乳頭癌の上皮成長因子受容体遺伝子変異

  入佐 薫; 真砂 勝泰; 阪森 優一; 冨樫 庸介; 金 永学; 三尾 直士; 三嶋 理晃

  肺癌, Feb. 2010

  
• Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer

  Akiko Fukuhara; Katsuhiro Masago; Masashi Neo; Shunsuke Fujibayashi; Shiro Fujita; Yukimasa Hatachi; Kaoru Irisa; Yuichi Sakamori; Yosuke Togashi; Young Hak Kim; Tadashi Mio; Michiaki Mishima

  Case Reports in Oncology, 2010, Peer-reviewed

  
• Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

  Katsuhiro Masago; Shiro Fujita; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Kaoru Irisa; Yuichi Sakamori; Chiyuki Okuda; Tadashi Mio; Michiaki Mishima

  Oncology, 2010, Peer-reviewed

  
• Octreotide, a Somatostatin Analogue, in the Treatment of Chylothorax Associated with Idiopathic Fibrosing Mediastinitis

  Yosuke Togashi; Young Hak Kim; Ryo Miyahara; Kaoru Irisa; Yuichi Sakamori; Katsuhiro Masago; Tadashi Mio; Hiroshi Date; Michiaki Mishima

  The Tohoku Journal of Experimental Medicine, 2010, Peer-reviewed

  

Misc.

• Overexpression of ABC transporters through HGF/c-MET activation results in anti-cancer drug resistance in SCLC

  Yoshitaka Yagi; Hiroaki Ozasa; Takahiro Tsuji; Yuichi Sakamori; Takeshi Nomizo; Hiroki Nagai; Young Hak Kim; Ken Maeno; Tetsuya Oguri; Michiaki Mishima

  CANCER RESEARCH, Jul. 2016

  
• CIRCULATING TUMOR CELLS AS A PROGNOSTIC MARKER IN METASTATIC NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY

  Y. Sakamori; Y. Kim; H. Yoshioka; M. Hirabayashi; K. Onaru; M. Fukui; T. Hirata; H. Nagai; H. Ozasa; M. Mishima

  ANNALS OF ONCOLOGY, Nov. 2013

  
• YAP1は抗Apoptosis因子Mcl-1とBcl-xLの発現調節を介して,ALK陽性肺癌細胞の初期生存を仲介する

  辻貴宏; 辻貴宏; 辻貴宏; 小笹裕晃; 青木航; 油屋駿介; 船造智子; 山添正敏; 味水瞳; 安田有斗; 野溝岳; 吉田博徳; 阪森優一; 和氣弘明; 和氣弘明; 植田充美; 平井豊博; 金永学

  日本肺癌学会学術集会号, 2020

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer

  H. Ajimizu; H. Ozasa; S. Sato; Y. Sakamori; T. Funazo; Y. Yasuda; T. Nomizo; T. Tsuji; H. Yoshida; Y. Yagi; H. Nagai; A. Sato; M. Tsuchiya; S. Muro; Y. Nagasaka; M. Mishima; Y. H. Kim

  ANNALS OF ONCOLOGY, Oct. 2016

  
• Increased ALDH7A1 expression enhances the resistance to the anticancer drugs and colony formation in lung cancer cell lines

  Yuichi Sakamori; Hiroaki Ozasa; Eiji Kunii; Yoshitaka Yagi; Takahiro Tsuji; Takeshi Nomizo; Hiroki Nagai; Young Hak Kim; Ken Maeno; Tetsuya Oguri; Michiaki Mishima

  CANCER RESEARCH, Jul. 2016

  
• 当院におけるALK融合遺伝子転座陽性進行非小細胞肺癌の使用経験

  安田 有斗; 辻 貴宏; 船造 智子; 野溝 岳; 八木 由生; 吉田 博徳; 阪森 優一; 永井 宏樹; 小笹 裕晃; 金 永学

  第104回日本肺癌学会関西支部学術集会, Jul. 2016

  
• Clinical significance of serum hepatocyte growth factor (sHGF) in patients with advanced non-small-cell lung cancer (NSCLC).

  Takahiro Tsuji; Yuichi Sakamori; Hiroaki Ozasa; Hitomi Ajimizu; Yoshitaka Yagi; Hiroki Nagai; Michiaki Mishima; Young Hak Kim

  JOURNAL OF CLINICAL ONCOLOGY, May 2015

  
• PHASE II STUDY OF PEMETREXED plus ERLOTINIB IN PRETREATED Non-Sq-NSCLC Pts WITH wtEGFR (TALIMTA STUDY)

  Takashi Nishimura; Young Hak Kim; Hiroki Nagai; Hiroaki Ozasa; Yuichi Sakamori; Shigeaki Iwatsubo; Tomoko Nishimura; Hironobu Sunadome; Toshiyuki Iwata; Michiaki Mishima

  ANNALS OF ONCOLOGY, Oct. 2014

  
• COPD合併非小細胞肺癌の予後

  味水 瞳; 小笹 裕晃; 佐藤 晋; 阪森 優一; 船造 智子; 安田 有斗; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 永井 宏樹; 佐藤 篤靖; 土谷 美知子; 室 繁郎; 長坂 行雄; 三嶋 理晃; 金 永学

  肺癌, Nov. 2016

  
• 脳転移患者におけるBevacizumab併用初回化学療法の後方視的検討

  八木 由生; 阪森 優一; 味水 瞳; 野溝 岳; 辻 貴宏; 永井 宏樹; 小笹 裕晃; 金 永学; 三嶋 理晃

  肺癌, Oct. 2015

  
• 進行非小細胞肺癌における血清HGFと臨床的予後の検討

  辻 貴宏; 阪森 優一; 小笹 裕晃; 八木 由生; 味水 瞳; 野溝 岳; 永井 宏樹; 金 永学; 三嶋 理晃

  肺癌, Oct. 2015

  
• カルボプラチン・パクリタキセル・ベバシズマブ併用療法が奏効した肺紡錘細胞癌の1例

  辻 貴宏; 金 永学; 永井 宏樹; 味水 瞳; 八木 由生; 阪森 優一; 小笠 裕晃; 三嶋 理晃

  肺癌, Aug. 2015

  
• 小細胞肺癌により傍腫瘍性神経症候群を来し、抗Hu抗体、抗Yo抗体、抗CV-2抗体が陽性であった1例

  織谷 康之; 味水 瞳; 小笹 裕晃; 野溝 岳; 阪森 優一; 永井 宏樹; 金 永学; 三嶋 理晃

  肺癌, Aug. 2015

  
• Single nucleotide polymorphisms in PD-L1 and outcome in nivolumab-treated advanced non-small-cell lung cancer patients

  T. Nomizo; T. Funazo; H. Ozasa; T. Tsuji; Y. Yasuda; H. Yoshida; Y. Sakamori; H. Nagai; T. Hirai; Y. H. Kim

  ANNALS OF ONCOLOGY, Sep. 2017

  
• 肺癌併存症・合併症 COPD合併肺癌の予後 COPD治療の意義

  味水 瞳; 佐藤 晋; 小笹 裕晃; 阪森 優一; 永井 宏樹; 佐藤 篤靖; 金 永学; 室 繁郎; 平井 豊博; 三嶋 理晃

  日本呼吸器学会誌, Mar. 2016

  
• 京大病院におけるチーム医療の取り組みと安全性対策 免疫チェックポイント阻害剤を安全に使用するために

  永井 宏樹; 金 永学; 大塚 篤司; 寺尾 真琴; 池見 泰明; 黒田 貴子; 浜辺 陽子; 安田 有斗; 船造 智子; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 阪森 優一; 小笹 裕晃; 松本 繁巳; 武藤 学

  肺癌, Nov. 2016

  
• PROGNOSTIC SIGNIFICANCE OF SYSTEMIC INFLAMMATORY RESPONSE AND EPIDERMAL GROWTH FACTOR RECEPTOR GENE STATUS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

  Yosuke Togashi; Katsuhiro Masago; Yuichi Sakamori; Young Hak Kim; Michiaki Mishima

  JOURNAL OF THORACIC ONCOLOGY, Jun. 2011

  
• Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab

  TOGASHI Yosuke; KIM Young Hak; MASAGO Katsuhiro; TAMAI Koji; SAKAMORI Yuichi; MIO Tadashi; MISHIMA Michiaki

  International journal of clinical oncology, 01 Aug. 2011

  

Presentations

• 当院におけるマルチ遺伝子検査の現況

  阪森優一

  希少肺癌カンファレンス, 21 Jun. 2022, Invited

  
• 肺癌ICI治療時の 患者指導と注意点

  阪森優一

  Lung Cancer Online Meeting in 京滋, 10 Jun. 2022

  
• 進展型小細胞肺癌のICI併用療法

  阪森優一

  但馬の肺癌診療を考える会, 02 May 2022

  
• コロナ禍におけるがん薬物療法

  阪森優一

  令和3年度 かかりつけ医（がん対応力）向上研修, 05 Mar. 2022

  
• 肺癌ICI治療時の患者指導と注意点

  阪森優一

  令和３年度 オンラインで学ぶ肺がん治療セミナー, 02 Sep. 2021

  
• 肺癌薬物療法の進歩

  阪森優一

  第4回 2025年に向けた薬剤師業務研究会in京都, 12 Feb. 2021

  
• 免疫チェックポイント阻害剤における副作用対策

  阪森優一

  令和3年度 第1回若手医師のための臨床に役立つ呼吸器セミナー, 31 Jan. 2021

  
• 

  切除不能胸腺癌に対する化学療法の後方視的解析

  阪森優一; 大木元達也; 細谷和貴; 山添正敏; 味水瞳; 辻貴宏; 糸谷涼; 吉田博徳; 小笹裕晃; 金永学; 平井豊博; 武藤学

  第61回日本肺癌学会学術集会, 13 Nov. 2020

  
• BRAF陽性肺癌にDabrafenib/Trametinibが投与された4例の検討

  藤原直樹; 阪森優一

  第111回日本肺癌学会関西支部学術集会, 22 Feb. 2020

  
• 免疫複合療法の副作用マネジメント

  阪森優一

  Breast Cancer Symposium In Kyoto, 20 Feb. 2020, Invited

  
• 非小細胞肺癌の薬物治療

  阪森優一

  第11回胸部腫瘍セミナー, 04 Oct. 2019, Invited

  
• Analysis of mutation profile by using Oncomine™ Lung cfDNA Assay in advanced non-small cell lung cancer patients with driver mutation

  阪森 優一; 金井 雅史; 吉田 博徳; 小笹 裕晃; 金 永学; 平井 豊博; 武藤 学

  第17回日本臨床腫瘍学会学術集会, 19 Jul. 2019

  
• Nivolumabが投与された大細胞神経内分泌癌(LCNEC) 4例の検討

  島佑介〇、阪森優一、吉田博徳、小笹裕晃、金永学、平井豊博

  第１１０回 肺癌学会関西支部地方会, 29 Jun. 2019

  
• 非小細胞肺癌における細胞障害性抗癌剤 ＋免疫チェックポイント阻害剤併用療法の 毒性及び使用経験

  阪森優一

  がん化学療法講演会 京都桂病院, 22 May 2019, Invited

  
• 当院におけるchemo combiの使用経験 ～副作用の観点から～

  阪森優一

  lung cancer conference in kyoto, 15 Mar. 2019, Invited

  
• 免疫チェックポイント阻害薬の 治療マネジメントについて

  阪森優一

  チームオンコロジーセミナー, 16 Feb. 2019, Invited

  
• 1. ドライバー変異陰性の非小細胞肺癌に対する2次治療としてのニボルマブとその他の抗癌剤との比較検討

  阪森 優一

  第59回日本肺癌学会学術集会, 30 Nov. 2018

  
• ドライバー遺伝子変異陽性肺癌における免疫チェックポイント阻害剤の治療効果についての検討

  阪森 優一

  第19回KTORG研究会, 14 Jul. 2018

  
• 遺伝子変異陰性例における進行期非小細胞肺癌の治療戦略

  阪森 優一

  豊岡毒性マネージメントセミナー, 18 May 2018, Invited

  
• Circulating tumor cells as a prognostic marker in metastatic non-small-cell lung cancer patients receiving chemotherapy.

  Yuichi Sakamori; Young Hak Kim; Hiroshige Yoshioka; Masataka Hirabayashi; Koichi Onaru; Motonari Fukui; Toshiki Hirata; Michiaki Mishima

  2013 ASCO Annual Meeting, 2013

  

Books and Other Publications

• 呼吸器内科 第40巻第1号

  阪森優一, Joint work, がんゲノム診断の現状と課題

  科学評論社, Jul. 2021

  
• 免疫チェックポイント阻害薬実践ガイドブック : 使いこなすためのコツ!

  阪森優一, Contributor, 腎機能障害

  メジカルビュー社, Oct. 2020

  Find Kyoto University's collection of books :

  

Works

• 免疫チェックポイント阻害剤の副作用対応マニュアル

  阪森優一; 船越太郎

  From 21 Dec. 2020

  

Academic, Social Contribution

Committee Memberships

• From Dec. 2022, To Present

  評議員, 日本肺癌学会

Academic Contribution

• 第63会 日本肺癌学会学術集会

  Panel moderator

  From 02 Dec. 2022